Literature DB >> 19955042

Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.

Otylia Kowal-Bielecka1, Jerome Avouac, David Pittrow, Doerte Huscher, Frank Behrens, Christopher P Denton, Ivan Foeldvari, Marc Humbert, Marco Matucci-Cerinic, Peter Nash, Christian F Opitz, Lewis J Rubin, James R Seibold, Vibeke Strand, Daniel E Furst, Oliver Distler.   

Abstract

OBJECTIVE: To assess the validation status of echocardiography with continuous Doppler (echo-Doppler) as an outcome measure in pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc).
METHODS: Structured literature review on full-text English articles was performed using the PubMed and Cochrane databases. Assessment of validation of echo-Doppler was based on the OMERACT filter criteria with the domains truth (face, content, construct, and criterion validity), discrimination, and feasibility.
RESULTS: Out of 35 studies eligible for analysis, only 5 included well defined PAH-SSc subgroups (World Health Organization criteria). Echo was considered as having face validity based on expert opinion and high number of studies using echo for evaluation of patients with SSc. Echo was considered partially validated with respect to criterion validity based on significant correlations between echo measures and right-heart catheterization in patients with SSc at risk of PAH/PH. However, echo was found to lack specificity (lack of content validity), since measurements of echo pulmonary pressure may be influenced by left-heart disease and interstitial lung disease. Data from general populations of patients with scleroderma indicate that evaluation of pulmonary artery pressure by echo might not be available in all PAH-SSc patients because of technical factors. No studies enabling evaluation of the discriminant capacity over time and treatment of echo in PAH-SSc could be identified.
CONCLUSION: Further studies are needed to fully validate echo-Doppler as an outcome measure in PAH-SSc. These studies would include cross-sectional analysis of baseline measures and longitudinal data of placebo and verum groups in randomized controlled trials of patients with PAH-SSc.

Entities:  

Mesh:

Year:  2009        PMID: 19955042     DOI: 10.3899/jrheum.090661

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.

Authors:  Theodoros Dimitroulas; Sophie Mavrogeni; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2012-02-07       Impact factor: 20.543

2.  Echocardiographic assessment of regional right ventricular systolic function using two-dimensional strain echocardiography and evaluation of the predictive ability of longitudinal 2D-strain imaging for pulmonary arterial hypertension in systemic sclerosis patients.

Authors:  Vedat Hekimsoy; Ergun Barıs Kaya; Ali Akdogan; Levent Sahiner; Banu Evranos; Ugur Canpolat; Kudret Aytemir; Necla Özer; Lale Tokgozoglu
Journal:  Int J Cardiovasc Imaging       Date:  2018-01-10       Impact factor: 2.357

Review 3.  An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.

Authors:  Geoffrey Kurland; Robin R Deterding; James S Hagood; Lisa R Young; Alan S Brody; Robert G Castile; Sharon Dell; Leland L Fan; Aaron Hamvas; Bettina C Hilman; Claire Langston; Lawrence M Nogee; Gregory J Redding
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

4.  Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis.

Authors:  Monica Mukherjee; Valentina Mercurio; Aparna Balasubramanian; Ami A Shah; Steven Hsu; Catherine E Simpson; Rachel Damico; Todd M Kolb; Paul M Hassoun; Stephen C Mathai
Journal:  Arthritis Res Ther       Date:  2022-06-18       Impact factor: 5.606

5.  Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension.

Authors:  Deepa M Gopal; Bryan Doldt; Kim Finch; Robert W Simms; Harrison W Farber; Noyan Gokce
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-09       Impact factor: 4.794

6.  Who should be referred to a specialist pulmonary -hypertension centre - a referrer's guide.

Authors:  Jay Suntharalingam; Rob MacKenzie Ross; Jacob Easaw; Graham Robinson; Gerry Coghlan
Journal:  Clin Med (Lond)       Date:  2016-04       Impact factor: 2.659

Review 7.  Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Authors:  Marc Humbert; Manjit Singh; Daniel E Furst; Dinesh Khanna; James R Seibold
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

8.  N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.

Authors:  Vivek Thakkar; Wendy M Stevens; David Prior; Owen A Moore; Jillian Byron; Danny Liew; Karen Patterson; Pravin Hissaria; Janet Roddy; Jane Zochling; Joanne Sahhar; Peter Nash; Kathleen Tymms; David Celermajer; Eli Gabbay; Peter Youssef; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2012-06-12       Impact factor: 5.156

9.  Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Authors:  Christopher P Denton; Jerome Avouac; Frank Behrens; Daniel E Furst; Ivan Foeldvari; Marc Humbert; Doerte Huscher; Otylia Kowal-Bielecka; Marco Matucci-Cerinic; Peter Nash; Christian F Opitz; David Pittrow; Lewis J Rubin; James R Seibold; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2011-06-20       Impact factor: 5.156

10.  The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.

Authors:  Vivek Thakkar; Wendy Stevens; David Prior; Peter Youssef; Danny Liew; Eli Gabbay; Janet Roddy; Jennifer G Walker; Jane Zochling; Joanne Sahhar; Peter Nash; Susan Lester; Maureen Rischmueller; Susanna M Proudman; Mandana Nikpour
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.